Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289351 · ClinicalTrials.gov registry record · Phase 4
Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis
A Phase 4 study, sponsored by Phoenix Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
NCT03289351 is a Phase 4 study that has completed, run by Phoenix Children's Hospital. The registered enrollment target is 162 participants.
The verdict
NCT03289351, a Phase 4 study, has completed, sponsored by Phoenix Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
Study Summary
After appendix has been removed for perforated appendicitis, patients will receive postoperative antibiotics. In the last 5 years, the literature has transitioned from a 3 -drug therapy to 2-drug therapy. Now there is a recent literature suggesting a single-drug therapy may be safe and adequate. In fact, using zosyn (piperacillin-tazobactam) as a single-drug therapy, there are additional benefits of simplicity, compliance, and lower infectious complications. Currently surgeons are already using both 2-drug regimen (ceftriaxone/metronidazole) and single-drug regimen (zosyn) interchangeable as both are FDA approved and regulated antibiotics for intra-abdominal infection. There is a clear need to compare outcomes between these two options.
Interventions
- DRUG Piperacillin, Tazobactam Drug Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-05-22 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289351
The ClinicalTrials.gov registry entry for NCT03289351 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix Children's Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Piperacillin, Tazobactam Drug Combination is the first listed.
NCT03289351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289351 about?
NCT03289351 is a clinical study titled "Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis". After appendix has been removed for perforated appendicitis, patients will receive postoperative antibiotics. In the last 5 years, the literature has transitioned from a 3 -drug therapy to 2-drug therapy. Now there is a recent literature suggesting a single-drug therapy may be safe and adequate. In ...
What is the current status of trial NCT03289351?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2017-05-22. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT03289351?
The interventions under investigation include: Piperacillin, Tazobactam Drug Combination (DRUG).
Who is sponsoring clinical trial NCT03289351?
This trial is sponsored by Phoenix Children's Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.